First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

NCT04000282 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi